Literature DB >> 10215625

Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein.

M Giovannini1, E Robanus-Maandag, M Niwa-Kawakita, M van der Valk, J M Woodruff, L Goutebroze, P Mérel, A Berns, G Thomas.   

Abstract

Specific mutations in some tumor suppressor genes such as p53 can act in a dominant fashion. We tested whether this mechanism may also apply for the neurofibromatosis type-2 gene (NF2) which, when mutated, leads to schwannoma development. Transgenic mice were generated that express, in Schwann cells, mutant NF2 proteins prototypic of natural mutants observed in humans. Mice expressing a NF2 protein with an interstitial deletion in the amino-terminal domain showed high prevalence of Schwann cell-derived tumors and Schwann cell hyperplasia, whereas those expressing a carboxy-terminally truncated protein were normal. Our results indicate that a subset of mutant NF2 alleles observed in patients may encode products with dominant properties when overexpressed in specific cell lineages.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215625      PMCID: PMC316642          DOI: 10.1101/gad.13.8.978

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  39 in total

Review 1.  Schwann cell differentiation.

Authors:  T S Zorick; G Lemke
Journal:  Curr Opin Cell Biol       Date:  1996-12       Impact factor: 8.382

2.  Defects in neurofibromatosis 2 protein function can arise at multiple levels.

Authors:  D H Gutmann; R T Geist; H m Xu; J S Kim; S Saporito-Irwin
Journal:  Hum Mol Genet       Date:  1998-03       Impact factor: 6.150

3.  Localization and functional domains of the neurofibromatosis type II tumor suppressor, merlin.

Authors:  R J Shaw; A I McClatchey; T Jacks
Journal:  Cell Growth Differ       Date:  1998-04

4.  Cre-mediated somatic site-specific recombination in mice.

Authors:  K Akagi; V Sandig; M Vooijs; M Van der Valk; M Giovannini; M Strauss; A Berns
Journal:  Nucleic Acids Res       Date:  1997-05-01       Impact factor: 16.971

5.  P0 promoter directs expression of reporter and toxin genes to Schwann cells of transgenic mice.

Authors:  A Messing; R R Behringer; J P Hammang; R D Palmiter; R L Brinster; G Lemke
Journal:  Neuron       Date:  1992-03       Impact factor: 17.173

6.  Cholinergic nerves in mouse uterus.

Authors:  M Moscarini; A Cantagalli; C Cavallotti; C De Luca; F Amenta
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

7.  Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas.

Authors:  P Mérel; K Hoang-Xuan; M Sanson; A Moreau-Aubry; E K Bijlsma; C Lazaro; J P Moisan; F Resche; I Nishisho; X Estivill
Journal:  Genes Chromosomes Cancer       Date:  1995-07       Impact factor: 5.006

8.  Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain.

Authors:  H Koga; N Araki; H Takeshima; T Nishi; T Hirota; Y Kimura; M Nakao; H Saya
Journal:  Oncogene       Date:  1998-08-20       Impact factor: 9.867

9.  Expression of nerve growth factor receptor in paraffin-embedded soft tissue tumors.

Authors:  P M Perosio; J J Brooks
Journal:  Am J Pathol       Date:  1988-07       Impact factor: 4.307

10.  Analysis of mutations in the SCH gene in schwannomas.

Authors:  E K Bijlsma; P Merel; D A Bosch; A Westerveld; O Delattre; G Thomas; T J Hulsebos
Journal:  Genes Chromosomes Cancer       Date:  1994-09       Impact factor: 5.006

View more
  37 in total

1.  Mouse tumor model for neurofibromatosis type 1.

Authors:  K S Vogel; L J Klesse; S Velasco-Miguel; K Meyers; E J Rushing; L F Parada
Journal:  Science       Date:  1999-12-10       Impact factor: 47.728

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

3.  Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.

Authors:  Kristy Truong; Iram Ahmad; J Jason Clark; Alison Seline; Tyler Bertroche; Brian Mostaert; Douglas J Van Daele; Marlan R Hansen
Journal:  Neuroscience       Date:  2018-02-03       Impact factor: 3.590

4.  Phosphorylation of Merlin by Aurora A kinase appears necessary for mitotic progression.

Authors:  Vinay Mandati; Laurence Del Maestro; Florent Dingli; Bérangère Lombard; Damarys Loew; Nicolas Molinie; Stephane Romero; Daniel Bouvard; Daniel Louvard; Alexis M Gautreau; Eric Pasmant; Dominique Lallemand
Journal:  J Biol Chem       Date:  2019-07-11       Impact factor: 5.157

5.  Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2.

Authors:  S M Messerli; Y Tang; M Giovannini; R Bronson; R Weissleder; X O Breakefield
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

6.  Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Authors:  Scott R Plotkin; Jaishri O Blakeley; D Gareth Evans; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine Messiaen; Laura Papi; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat O Stemmer-Rachamimov; Jeremie Vitte; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2013-02-07       Impact factor: 2.802

Review 7.  The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.

Authors:  M E Baser; L Kuramoto; R Woods; H Joe; J M Friedman; A J Wallace; R T Ramsden; S Olschwang; E Bijlsma; M Kalamarides; L Papi; R Kato; J Carroll; C Lázaro; F Joncourt; D M Parry; G A Rouleau; D G R Evans
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

Review 8.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

9.  Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter.

Authors:  S Prabhakar; G J Brenner; B Sung; S M Messerli; J Mao; M Sena-Esteves; A Stemmer-Rachamimov; B Tannous; X O Breakefield
Journal:  Cancer Gene Ther       Date:  2009-10-16       Impact factor: 5.987

10.  Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2.

Authors:  Karo Tanaka; Ascia Eskin; Fabrice Chareyre; Walter J Jessen; Jan Manent; Michiko Niwa-Kawakita; Ruihong Chen; Cory H White; Jeremie Vitte; Zahara M Jaffer; Stanley F Nelson; Allan E Rubenstein; Marco Giovannini
Journal:  Clin Cancer Res       Date:  2013-05-28       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.